Patents Assigned to PharmaIN
-
Publication number: 20200254100Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.Type: ApplicationFiled: March 25, 2020Publication date: August 13, 2020Applicant: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin, Akiko Nashimoto-Ashfield
-
Patent number: 10624966Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.Type: GrantFiled: June 14, 2018Date of Patent: April 21, 2020Assignee: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin, Akiko Nashimoto-Ashfield
-
Publication number: 20200017567Abstract: This disclosure provides a natriuretic peptide derivative of Formula (I), and to compositions including a natriuretic peptide derivative of Formula (I), (fatty acyl)z-(B)x-(G)y-NP?? (I), wherein: z is 1, x is an integer from 2 to 4 and y is 3; or z is 0, x is an integer from 0 to 4 and y is an integer from 1 to 3; fatty acyl comprises from 12 to 24 (e.g., 12 to 18) carbons atoms; B is lysine or arginine; G is glycine; NP is a natriuretic peptide; if present, (fatty acyl)z- is covalently linked to the N-terminus of (B)x; (fatty acyl)z-(B)x- is covalently linked to the N-terminus of (G)y; and (fatty acyl)z-(B)x-(G)y- is covalently linked to the N-terminus of NP. The natriuretic peptide derivative according to the disclosure, and compositions thereof, are useful in the treatment of diseases such as hypertension, vascular congestion, and heart disease.Type: ApplicationFiled: September 20, 2019Publication date: January 16, 2020Applicant: PharmaIn CorporationInventors: Gerardo M. Castillo, Akiko Nishimoto-Ashfield, Elijah M. Bolotin
-
Patent number: 10507248Abstract: The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.Type: GrantFiled: August 9, 2017Date of Patent: December 17, 2019Assignee: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Publication number: 20180312642Abstract: Provided herein is a process of preparing a semi-random graft co-polymer, the product of which is difficult to fully characterize chemically. The product of the present disclosure has unique and useful properties of 1) binding to a peptide and 2) upon co-administration of the product and the peptide into animals the product prolongs the blood circulation time and elevates the level of the peptide, compared to the peptide alone without the product of the disclosure.Type: ApplicationFiled: July 9, 2018Publication date: November 1, 2018Applicant: PharmaIN CorporationInventors: Cynthia C. Jones, Joshua F. Alfaro, Gerardo M. Castillo
-
Publication number: 20180280516Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.Type: ApplicationFiled: June 14, 2018Publication date: October 4, 2018Applicant: PharmaIN CorporationInventors: Gerardo Castillo, Elijah M. Bolotin, Akiko Nashimoto-Ashfield
-
Patent number: 10035885Abstract: Provided herein is a process of preparing a semi-random graft co-polymer, the product of which is difficult to fully characterize chemically. The product of the present disclosure has unique and useful properties of 1) binding to a peptide and 2) upon co-administration of the product and the peptide into animals the product prolongs the blood circulation time and elevates the level of the peptide, compared to the peptide alone without the product of the disclosure.Type: GrantFiled: November 3, 2015Date of Patent: July 31, 2018Assignee: PharmaIN CorporationInventors: Cynthia C. Jones, Joshua F. Alfaro, Gerardo M. Castillo
-
Patent number: 10010613Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.Type: GrantFiled: September 8, 2010Date of Patent: July 3, 2018Assignee: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin, Akiko Nashimoto-Ashfield
-
Publication number: 20170368190Abstract: The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.Type: ApplicationFiled: August 9, 2017Publication date: December 28, 2017Applicant: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Patent number: 9657078Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidiodacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.Type: GrantFiled: June 15, 2015Date of Patent: May 23, 2017Assignee: PHARMAIN CORPORATIONInventors: Gerardo M. Castillo, Elijah Bolotin
-
Patent number: 9562111Abstract: The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments, the weight ratio of hydrophilic protective chains to hydrophobic moieties in the carrier is at least 15:1. In other embodiments, at least 90% of the residues of the polymeric backbone are coupled to a hydrophilic polymeric protective chain or a hydrophobic moiety. In other embodiments, the composition further comprises (iv) a hydrophobic load molecule dissociably linked to the hydrophobic moiety of the carrier.Type: GrantFiled: February 20, 2015Date of Patent: February 7, 2017Assignee: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah Bolotin
-
Publication number: 20160362523Abstract: Provided herein is a process of preparing a semi-random graft co-polymer, the product of which is difficult to fully characterize chemically. The product of the present disclosure has unique and useful properties of 1) binding to a peptide and 2) upon co-administration of the product and the peptide into animals the product prolongs the blood circulation time and elevates the level of the peptide, compared to the peptide alone without the product of the disclosure.Type: ApplicationFiled: November 3, 2015Publication date: December 15, 2016Applicant: PharmaIN CorporationInventors: Cynthia C. JONES, Joshua F. ALFARO, Gerardo M. CASTILLO
-
Publication number: 20150307578Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidiodacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.Type: ApplicationFiled: June 15, 2015Publication date: October 29, 2015Applicant: PHARMAIN CORPORATIONInventors: Gerardo M. Castillo, Elijah Bolotin
-
Publication number: 20150284476Abstract: The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments, the weight ratio of hydrophilic protective chains to hydrophobic moieties in the carrier is at least 15:1. In other embodiments, at least 90% of the residues of the polymeric backbone are coupled to a hydrophilic polymeric protective chain or a hydrophobic moiety. In other embodiments, the composition further comprises (iv) a hydrophobic load molecule dissociably linked to the hydrophobic moiety of the carrier.Type: ApplicationFiled: February 20, 2015Publication date: October 8, 2015Applicant: PHARMAIN CORPORATIONInventors: Gerardo M. Castillo, Elijah Bolotin
-
Patent number: 9090664Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.Type: GrantFiled: July 26, 2013Date of Patent: July 28, 2015Assignee: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Patent number: 8999930Abstract: The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments, the weight ratio of hydrophilic protective chains to hydrophobic moieties in the carrier is at least 15:1. In other embodiments, at least 90% of the residues of the polymeric backbone are coupled to a hydrophilic polymeric protective chain or a hydrophobic moiety. In other embodiments, the composition further comprises (iv) a hydrophobic load molecule dissociably linked to the hydrophobic moiety of the carrier.Type: GrantFiled: February 24, 2010Date of Patent: April 7, 2015Assignee: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Publication number: 20140154203Abstract: The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.Type: ApplicationFiled: November 22, 2013Publication date: June 5, 2014Applicant: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Patent number: 8563527Abstract: The present invention relates, in part, to an oligonucleotide-core carrier comprising a carrier, and oligonucleotide groups covalently linked to the carrier. The oligonucleotide groups are capable of dissociably linking load molecules such as therapeutic agents. The oligonucleotide-core carrier may also comprise protective side chains, and targeting molecules.Type: GrantFiled: August 19, 2008Date of Patent: October 22, 2013Assignee: Pharmain CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin, Alexei A. Bogdanov, Jr.
-
Patent number: 8277776Abstract: This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion.Type: GrantFiled: November 24, 2009Date of Patent: October 2, 2012Assignee: PharmaIN CorporationInventors: Elijah M. Bolotin, Gerardo M. Castillo
-
Patent number: 8257682Abstract: This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion.Type: GrantFiled: August 31, 2009Date of Patent: September 4, 2012Assignee: PharmaIn CorporationInventors: Elijah M. Bolotin, Gerardo M. Castillo